Maresin 1 Alleviates Diabetic Kidney Disease via LGR6-Mediated cAMP-SOD2-ROS Pathway.

Abstract

BACKGROUND:

Chronic hyperglycemia-induced inflammation is recognized as the most important pathophysiological process in diabetic kidney disease (DKD). As maresin 1 (MaR1) is an extensive anti-inflammatory lipid mediator, the present study investigated the protective role of MaR1 in the pathogenesis of DKD and its clinical relevance.

METHODS:

Serum MaR1 concentrations were analyzed in 104 subjects with normal glucose tolerant, type 2 diabetes (T2DM), or DKD. Streptozotocin (STZ) together with high fat diet was used to induce male C57BL/6 J mice into diabetic mice which were treated with MaR1. Human renal tubule epithelial cells (HK-2 cells) were treated by high glucose for glucotoxicity cell model and transfected with LGR6 siRNA for knockdown with MaR1 added，and detected oxidative stress and inflammatory related factors.

RESULTS:

Serum MaR1 concentrations were significant decreased in T2DM with or without kidney disease compared with normal participant and were lowest in patients with DKD. Serum MaR1 concentrations were negatively correlated with hemoglobin A1c (HbA1c), duration of diabetes, urinary albumin to creatinine ratio (UACR), neutrophil, and neutrophil-lymphocyte ratio and were positively correlated with high-density lipoprotein-cholesterol (HDL-C) and estimated glomerular filtration rate (eGFR). In mouse model, MaR1 injection alleviated hyperglycemia, UACR and the pathological progression of DKD. Interestingly, the renal expression of LGR6 was down-regulated in DKD and high glucose treated HK-2 cells but up-regulated by MaR1 treatment. Mechanistically, MaR1 alleviated inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway in DKD mice and high glucose treated HK-2 cells.

CONCLUSIONS:

Our study demonstrates that decreased serum MaR1 levels were correlated with the development of DKD. MaR1 could alleviate DKD and glucotoxicity-induced inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway. Thus, our present findings identify MaR1 as a predictor and a potential therapeutic target for DKD.

• Authors: Xinyue Li, Butuo Xu, Jing Wu, Yueli Pu, Shengrong Wan, Yan Zeng, Mei Wang, Lifang Luo, Fanjie Zhang, Zongzhe Jiang, Yong Xu
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2022 Pg. 7177889 ( 2022) ISSN: 1942-0994 [Electronic] United States
• PMID: 35498124 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Xinyue Li et al.

Chemical References

• 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
• Antioxidants
• LGR6 protein, human
• Lgr6 protein, mouse
• Reactive Oxygen Species
• Receptors, G-Protein-Coupled
• Docosahexaenoic Acids
• Glucose

Topics

• Animals
• Antioxidants
• Diabetes Mellitus, Experimental (metabolism)
• Diabetes Mellitus, Type 2 (complications)
• Diabetic Nephropathies (metabolism)
• Docosahexaenoic Acids
• Female
• Glucose
• Humans
• Hyperglycemia (complications)
• Inflammation
• Male
• Mice
• Mice, Inbred C57BL
• Reactive Oxygen Species
• Receptors, G-Protein-Coupled